Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BLZ-100 in Adult Glioma Surgery
NCT02234297Phase 1Completed
- Sponsor
- Blaze Bioscience
- Start
- Oct 2014
- Primary completion
- Feb 2016
- Modality
- Peptide-Drug Conjugates
- Countries
- 2
01
Overview
Phase 1, open-label, single-arm trial of tozuleristide in glioma, sponsored by Blaze Bioscience. Primary endpoint: Number of participants with adverse events at 7 days. Started Oct 2014; status: completed.
02
Drugs
tozuleristide
03
Conditions
glioma
Beyond the preview
Go deeper on NCT02234297.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02234297.